U.S. markets open in 6 hours 27 minutes

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.17-1.70 (-3.71%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close45.87
Open45.74
Bid0.00 x 800
Ask0.00 x 900
Day's Range42.78 - 46.00
52 Week Range22.06 - 64.54
Volume109,482
Avg. Volume151,461
Market Cap1.244B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-23.02
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021

    Upgrades For CVR Energy Inc (NYSE:CVI), Credit Suisse upgraded the previous rating of Underperform to Neutral. In the third quarter, CVR Energy showed an EPS of $0.57, compared to $1.18 from the year-ago quarter. At the moment, the stock has a 52-week-high of $35.63 and a 52-week-low of $9.81. CVR Energy closed at $21.13 at the end of the last trading period. Credit Suisse upgraded the previous rating for Par Pacific Holdings Inc (NYSE:PARR) from Underperform to Neutral. In the third quarter, Par Pacific Hldgs showed an EPS of $1.06, compared to $0.13 from the year-ago quarter. The stock has a 52-week-high of $20.43 and a 52-week-low of $5.72. At the end of the last trading period, Par Pacific Hldgs closed at $15.40. RBC Capital upgraded the previous rating for Bausch Health Companies Inc (NYSE:BHC) from Sector Perform to Outperform. In the third quarter, Bausch Health Cos showed an EPS of $1.32, compared to $1.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $32.25 and a 52-week-low of $11.15. Bausch Health Cos closed at $31.48 at the end of the last trading period. For Black Knight Inc (NYSE:BKI), Susquehanna upgraded the previous rating of Neutral to Positive. Black Knight earned $0.60 in the fourth quarter, compared to $0.54 in the year-ago quarter. The current stock performance of Black Knight shows a 52-week-high of $97.19 and a 52-week-low of $50.01. Moreover, at the end of the last trading period, the closing price was at $82.05. For Anterix Inc (NASDAQ:ATEX), JP Morgan upgraded the previous rating of Neutral to Overweight. At the moment, the stock has a 52-week-high of $57.75 and a 52-week-low of $27.27. Anterix closed at $40.55 at the end of the last trading period. According to Jefferies, the prior rating for Oshkosh Corp (NYSE:OSK) was changed from Hold to Buy. In the first quarter, Oshkosh showed an EPS of $1.13, compared to $1.10 from the year-ago quarter. The stock has a 52-week-high of $100.77 and a 52-week-low of $46.72. At the end of the last trading period, Oshkosh closed at $99.14. For Palantir Technologies Inc (NYSE:PLTR), Goldman Sachs upgraded the previous rating of Neutral to Buy. In the fourth quarter, Palantir Technologies earned $0.06. The current stock performance of Palantir Technologies shows a 52-week-high of $45.00 and a 52-week-low of $8.90. Moreover, at the end of the last trading period, the closing price was at $27.84. KeyBanc upgraded the previous rating for Rexnord Corp (NYSE:RXN) from Sector Weight to Overweight. In the third quarter, Rexnord showed an EPS of $0.39, compared to $0.48 from the year-ago quarter. The current stock performance of Rexnord shows a 52-week-high of $49.08 and a 52-week-low of $18.87. Moreover, at the end of the last trading period, the closing price was at $45.11. According to KeyBanc, the prior rating for Regal Beloit Corp (NYSE:RBC) was changed from Sector Weight to Overweight. For the fourth quarter, Regal Beloit had an EPS of $1.78, compared to year-ago quarter EPS of $1.25. The current stock performance of Regal Beloit shows a 52-week-high of $146.97 and a 52-week-low of $51.99. Moreover, at the end of the last trading period, the closing price was at $133.19. See all analyst ratings upgrades. Downgrades Truist Securities downgraded the previous rating for KAR Auction Services Inc (NYSE:KAR) from Buy to Hold. For the fourth quarter, KAR Auction Services had an EPS of $0.01, compared to year-ago quarter EPS of $0.19. The current stock performance of KAR Auction Services shows a 52-week-high of $23.53 and a 52-week-low of $9.41. Moreover, at the end of the last trading period, the closing price was at $18.45. Roth Capital downgraded the previous rating for Kodiak Sciences Inc (NASDAQ:KOD) from Buy to Neutral. In the third quarter, Kodiak Sciences showed an EPS of $0.80, compared to $0.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $171.21 and a 52-week-low of $35.49. Kodiak Sciences closed at $145.58 at the end of the last trading period. For KAR Auction Services Inc (NYSE:KAR), Guggenheim downgraded the previous rating of Neutral to Sell. KAR Auction Services earned $0.01 in the fourth quarter, compared to $0.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.53 and a 52-week-low of $9.41. KAR Auction Services closed at $18.45 at the end of the last trading period. For Palantir Technologies Inc (NYSE:PLTR), William Blair downgraded the previous rating of Market Perform to Underperform. Palantir Technologies earned $0.06 in the fourth quarter. The stock has a 52-week-high of $45.00 and a 52-week-low of $8.90. At the end of the last trading period, Palantir Technologies closed at $27.84. Morgan Stanley downgraded the previous rating for Fortive Corp (NYSE:FTV) from Overweight to Equal-Weight. For the fourth quarter, Fortive had an EPS of $0.70, compared to year-ago quarter EPS of $1.03. At the moment, the stock has a 52-week-high of $82.12 and a 52-week-low of $37.31. Fortive closed at $69.85 at the end of the last trading period. For Cortexyme Inc (NASDAQ:CRTX), Jefferies downgraded the previous rating of Buy to Hold. In the third quarter, Cortexyme showed an EPS of $0.73, compared to $0.37 from the year-ago quarter. The current stock performance of Cortexyme shows a 52-week-high of $73.84 and a 52-week-low of $26.66. Moreover, at the end of the last trading period, the closing price was at $30.72. JP Morgan downgraded the previous rating for bluebird bio Inc (NASDAQ:BLUE) from Overweight to Neutral. For the third quarter, bluebird bio had an EPS of $2.94, compared to year-ago quarter EPS of $3.73. The stock has a 52-week-high of $90.63 and a 52-week-low of $26.11. At the end of the last trading period, bluebird bio closed at $28.44. See all analyst ratings downgrades. Initiations With an Overweight rating, Wells Fargo initiated coverage on Chesapeake Energy Corp (NASDAQ:CHK). The price target seems to have been set at $54.00 for Chesapeake Energy. The current stock performance of Chesapeake Energy shows a 52-week-high of $77.50 and a 52-week-low of $0.12. Moreover, at the end of the last trading period, the closing price was at $43.55. Roth Capital initiated coverage on DiaMedica Therapeutics Inc (NASDAQ:DMAC) with a Buy rating. The price target for DiaMedica Therapeutics is set to $38.00. For the third quarter, DiaMedica Therapeutics had an EPS of $0.19, compared to year-ago quarter EPS of $0.20. The current stock performance of DiaMedica Therapeutics shows a 52-week-high of $10.88 and a 52-week-low of $1.87. Moreover, at the end of the last trading period, the closing price was at $9.40. Needham initiated coverage on Cormedix Inc (NASDAQ:CRMD) with a Buy rating. The price target for Cormedix is set to $31.00. The stock has a 52-week-high of $17.14 and a 52-week-low of $2.16. At the end of the last trading period, Cormedix closed at $13.99. With an Outperform rating, BMO Capital initiated coverage on Phathom Pharmaceuticals Inc (NASDAQ:PHAT). The price target seems to have been set at $63.00 for Phathom Pharmaceuticals. Phathom Pharmaceuticals earned $1.02 in the third quarter, compared to $1.07 in the year-ago quarter. The stock has a 52-week-high of $64.54 and a 52-week-low of $22.06. At the end of the last trading period, Phathom Pharmaceuticals closed at $42.80. With an Overweight rating, Barclays initiated coverage on IDEXX Laboratories Inc (NASDAQ:IDXX). The price target seems to have been set at $600.00 for IDEXX Laboratories. IDEXX Laboratories earned $1.76 in the fourth quarter, compared to $1.04 in the year-ago quarter. The current stock performance of IDEXX Laboratories shows a 52-week-high of $548.58 and a 52-week-low of $168.65. Moreover, at the end of the last trading period, the closing price was at $538.16. With an Overweight rating, Barclays initiated coverage on Covetrus Inc (NASDAQ:CVET). The price target seems to have been set at $48.00 for Covetrus. For the third quarter, Covetrus had an EPS of $0.26, compared to year-ago quarter EPS of $0.17. The stock has a 52-week-high of $40.77 and a 52-week-low of $4.04. At the end of the last trading period, Covetrus closed at $37.58. With a Buy rating, DA Davidson initiated coverage on First Citizens BancShares Inc (NASDAQ:FCNCA). The price target seems to have been set at $875.00 for First Citizens BancShares. First Citizens BancShares earned $13.59 in the fourth quarter, compared to $9.55 in the year-ago quarter. The current stock performance of First Citizens BancShares shows a 52-week-high of $749.50 and a 52-week-low of $276.08. Moreover, at the end of the last trading period, the closing price was at $746.00. With a Buy rating, HC Wainwright & Co. initiated coverage on Oncolytics Biotech Inc (NASDAQ:ONCY). The price target seems to have been set at $15.00 for Oncolytics Biotech. For the third quarter, Oncolytics Biotech had an EPS of $0.12, compared to year-ago quarter EPS of $0.16. The stock has a 52-week-high of $4.19 and a 52-week-low of $0.94. At the end of the last trading period, Oncolytics Biotech closed at $3.01. Goldman Sachs initiated coverage on Patria Investments Ltd (NASDAQ:PAX) with a Buy rating. The price target for Patria Investments is set to $28.00. The stock has a 52-week-high of $23.28 and a 52-week-low of $17.23. At the end of the last trading period, Patria Investments closed at $22.38. With a Buy rating, BTIG initiated coverage on Vuzix Corporation (NASDAQ:VUZI). The price target seems to have been set at $30.00 for Vuzix. For the third quarter, Vuzix had an EPS of $0.13, compared to year-ago quarter EPS of $0.18. The current stock performance of Vuzix shows a 52-week-high of $17.36 and a 52-week-low of $0.86. Moreover, at the end of the last trading period, the closing price was at $17.16. KeyBanc initiated coverage on Howmet Aerospace Inc (NYSE:HWM) with an Overweight rating. The price target for Howmet Aerospace is set to $36.00. For the fourth quarter, Howmet Aerospace had an EPS of $0.21, compared to year-ago quarter EPS of $0.53. The stock has a 52-week-high of $29.10 and a 52-week-low of $9.87. At the end of the last trading period, Howmet Aerospace closed at $28.37. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Preview: GlobantEarnings Preview for OPKO Health© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021

    Upgrades According to Summit Insights Group, the prior rating for ON Semiconductor Corp (NASDAQ:ON) was changed from Hold to Buy. For the fourth quarter, ON Semiconductor had an EPS of $0.35, compared to year-ago quarter EPS of $0.30. The current stock performance of ON Semiconductor shows a 52-week-high of $39.43 and a 52-week-low of $8.17. Moreover, at the end of the last trading period, the closing price was at $36.71. Barclays upgraded the previous rating for Dr Reddy's Laboratories Ltd (NYSE:RDY) from Equal-Weight to Overweight. Dr Reddy's Laboratories earned $0.02 in the third quarter, compared to $0.63 in the year-ago quarter. The stock has a 52-week-high of $73.50 and a 52-week-low of $33.33. At the end of the last trading period, Dr Reddy's Laboratories closed at $59.17. For Palo Alto Networks Inc (NYSE:PANW), Credit Suisse upgraded the previous rating of Neutral to Outperform. For the first quarter, Palo Alto Networks had an EPS of $1.62, compared to year-ago quarter EPS of $1.05. The stock has a 52-week-high of $375.00 and a 52-week-low of $125.47. At the end of the last trading period, Palo Alto Networks closed at $361.58. Evercore ISI Group upgraded the previous rating for Tetra Technologies Inc (NYSE:TTI) from Underperform to Outperform. In the third quarter, Tetra Technologies showed an EPS of $0.09, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $1.62 and a 52-week-low of $0.22. Tetra Technologies closed at $1.52 at the end of the last trading period. Goldman Sachs upgraded the previous rating for Dell Technologies Inc (NYSE:DELL) from Neutral to Buy. Dell Technologies earned $2.03 in the third quarter, compared to $1.75 in the year-ago quarter. The current stock performance of Dell Technologies shows a 52-week-high of $77.72 and a 52-week-low of $25.51. Moreover, at the end of the last trading period, the closing price was at $74.00. According to Credit Suisse, the prior rating for Rio Tinto PLC (NYSE:RIO) was changed from Neutral to Outperform. The stock has a 52-week-high of $86.90 and a 52-week-low of $35.35. At the end of the last trading period, Rio Tinto closed at $78.48. See all analyst ratings upgrades. Downgrades Credit Suisse downgraded the previous rating for BHP Group Ltd (NYSE:BHP) from Outperform to Neutral. The current stock performance of BHP Group shows a 52-week-high of $74.41 and a 52-week-low of $29.78. Moreover, at the end of the last trading period, the closing price was at $68.38. For Limelight Networks Inc (NASDAQ:LLNW), Cowen & Co. downgraded the previous rating of Outperform to Market Perform. Limelight Networks earned $0.01 in the third quarter, compared to $0.01 in the year-ago quarter. At the moment, the stock has a 52-week-high of $8.19 and a 52-week-low of $3.43. Limelight Networks closed at $4.67 at the end of the last trading period. Compass Point downgraded the previous rating for Hilltop Holdings Inc (NYSE:HTH) from Buy to Neutral. For the fourth quarter, Hilltop Holdings had an EPS of $1.30, compared to year-ago quarter EPS of $0.54. The current stock performance of Hilltop Holdings shows a 52-week-high of $33.69 and a 52-week-low of $11.05. Moreover, at the end of the last trading period, the closing price was at $30.85. According to Piper Sandler, the prior rating for argenx SE (NASDAQ:ARGX) was changed from Overweight to Neutral. For the third quarter, argenx had an EPS of $3.96, compared to year-ago quarter EPS of $0.72. The current stock performance of argenx shows a 52-week-high of $321.66 and a 52-week-low of $103.75. Moreover, at the end of the last trading period, the closing price was at $317.40. See all analyst ratings downgrades. Initiations Stephens & Co. initiated coverage on Zix Corp (NASDAQ:ZIXI) with an Overweight rating. The price target for Zix is set to $11.00. In the third quarter, Zix showed an EPS of $0.17, compared to $0.13 from the year-ago quarter. The current stock performance of Zix shows a 52-week-high of $9.46 and a 52-week-low of $2.84. Moreover, at the end of the last trading period, the closing price was at $8.32. MKM Partners initiated coverage on Poshmark Inc (NASDAQ:POSH) with a Buy rating. The price target for Poshmark is set to $88.00. The stock has a 52-week-high of $104.98 and a 52-week-low of $67.18. At the end of the last trading period, Poshmark closed at $73.00. Guggenheim initiated coverage on Phathom Pharmaceuticals Inc (NASDAQ:PHAT) with a Buy rating. The price target for Phathom Pharmaceuticals is set to $60.00. For the third quarter, Phathom Pharmaceuticals had an EPS of $1.02, compared to year-ago quarter EPS of $1.07. The stock has a 52-week-high of $64.54 and a 52-week-low of $22.06. At the end of the last trading period, Phathom Pharmaceuticals closed at $38.49. Wells Fargo initiated coverage on Gracell Biotechnologies Inc (NASDAQ:GRCL) with an Overweight rating. At the moment, the stock has a 52-week-high of $28.88 and a 52-week-low of $20.12. Gracell Biotechnologies closed at $21.81 at the end of the last trading period. Morgan Stanley initiated coverage on Stride Inc (NYSE:LRN) with a Equal-Weight rating. The price target for Stride is set to $27.00. The stock has a 52-week-high of $52.84 and a 52-week-low of $15.06. At the end of the last trading period, Stride closed at $27.20. Jefferies initiated coverage on Gracell Biotechnologies Inc (NASDAQ:GRCL) with a Buy rating. The price target for Gracell Biotechnologies is set to $30.00. At the moment, the stock has a 52-week-high of $28.88 and a 52-week-low of $20.12. Gracell Biotechnologies closed at $21.81 at the end of the last trading period. Morgan Stanley initiated coverage on Chart Industries Inc (NYSE:GTLS) with an Overweight rating. The price target for Chart Industries is set to $135.00. Chart Industries earned $0.80 in the third quarter, compared to $0.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $143.56 and a 52-week-low of $15.00. Chart Industries closed at $127.54 at the end of the last trading period. With an Outperform rating, SVB Leerink initiated coverage on Cullinan Management Inc (NASDAQ:CGEM). The price target seems to have been set at $52.00 for Cullinan Management. The stock has a 52-week-high of $43.00 and a 52-week-low of $27.01. At the end of the last trading period, Cullinan Management closed at $33.77. With a Buy rating, Citigroup initiated coverage on Clover Health Investments Corp (NASDAQ:CLOV). The price target seems to have been set at $19.00 for Clover Health Investments. The stock has a 52-week-high of $17.24 and a 52-week-low of $13.10. At the end of the last trading period, Clover Health Investments closed at $13.81. Stephens & Co. initiated coverage on Mimecast Ltd (NASDAQ:MIME) with an Overweight rating. The price target for Mimecast is set to $57.00. In the second quarter, Mimecast showed an EPS of $0.32, compared to $0.13 from the year-ago quarter. The current stock performance of Mimecast shows a 52-week-high of $59.48 and a 52-week-low of $25.14. Moreover, at the end of the last trading period, the closing price was at $44.45. Stephens & Co. initiated coverage on Proofpoint Inc (NASDAQ:PFPT) with an Overweight rating. The price target for Proofpoint is set to $165.00. For the third quarter, Proofpoint had an EPS of $0.59, compared to year-ago quarter EPS of $0.49. The current stock performance of Proofpoint shows a 52-week-high of $140.91 and a 52-week-low of $83.81. Moreover, at the end of the last trading period, the closing price was at $130.62. Stephens & Co. initiated coverage on Ping Identity Holding Corp (NYSE:PING) with an Overweight rating. The price target for Ping Identity Holding is set to $40.00. For the third quarter, Ping Identity Holding had an EPS of $0.11, compared to year-ago quarter EPS of $0.13. The current stock performance of Ping Identity Holding shows a 52-week-high of $37.80 and a 52-week-low of $12.02. Moreover, at the end of the last trading period, the closing price was at $30.83. With an Outperform rating, Raymond James initiated coverage on Neurocrine Biosciences Inc (NASDAQ:NBIX). The price target seems to have been set at $163.00 for Neurocrine Biosciences. Neurocrine Biosciences earned $0.97 in the third quarter, compared to $0.90 in the year-ago quarter. The stock has a 52-week-high of $136.26 and a 52-week-low of $72.14. At the end of the last trading period, Neurocrine Biosciences closed at $106.02. With an Overweight rating, Piper Sandler initiated coverage on Gracell Biotechnologies Inc (NASDAQ:GRCL). The price target seems to have been set at $40.00 for Gracell Biotechnologies. At the moment, the stock has a 52-week-high of $28.88 and a 52-week-low of $20.12. Gracell Biotechnologies closed at $21.81 at the end of the last trading period. Piper Sandler initiated coverage on Surgalign Holdings Inc (NASDAQ:SRGA) with an Overweight rating. The price target for Surgalign Holdings is set to $4.00. For the third quarter, Surgalign Holdings had an EPS of $0.11, compared to year-ago quarter EPS of $0.01. At the moment, the stock has a 52-week-high of $3.15 and a 52-week-low of $1.49. Surgalign Holdings closed at $1.70 at the end of the last trading period. With an Overweight rating, Piper Sandler initiated coverage on Nevro Corp (NYSE:NVRO). The price target seems to have been set at $190.00 for Nevro. Nevro earned $0.29 in the third quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Nevro shows a 52-week-high of $188.14 and a 52-week-low of $65.05. Moreover, at the end of the last trading period, the closing price was at $163.86. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Outlook For Axalta Coating SystemsA Preview Of KLA's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

    Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan in combination with amoxicillin (vonoprazan dual therapy) and vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) for the eradication of H. pylori infection. Phathom continues to expect topline results from the study in the second quarter of 2021. PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients with H. pylori infection. Participants are evenly randomized to one of three arms: vonoprazan 20 mg administered twice a day (BID) and amoxicillin 1g administered three times a day (TID); vonoprazan 20 mg BID, amoxicillin 1g BID and clarithromycin 500 mg BID; and lansoprazole 30 mg BID, amoxicillin 1g BID and clarithromycin 500 mg BID. Each treatment regimen is administered for 14 days. The primary endpoint is the percentage of patients with successful eradication of H. pylori infection. “The completion of patient enrollment in the PHALCON-HP trial marks another significant milestone for Phathom and for the millions of people with H. pylori infection. In the U.S. and Europe, one-in-three adults are believed to carry H. pylori, which, if left untreated, can lead to dyspeptic symptoms, ulcers, and gastric cancer. These regions are experiencing declining H. pylori eradication rates due to increasing antibiotic resistance which we believe can be addressed with more potent inhibition of gastric acid. Our ability to enroll patients in the PHALCON-HP trial during a pandemic highlights the demand for new therapeutic regimens to combat this chronic bacterial infection,” said Azmi Nabulsi, M.D., Phathom’s Chief Operating Officer. “Phathom greatly appreciates the commitment and execution of our investigators and clinicians involved in PHALCON-HP and thanks all our patient volunteers for their participation.” PHALCON-HP is one of two Phase 3 trials evaluating vonoprazan in gastrointestinal diseases. The second trial, PHALCON-EE, is a randomized, double-blind, two-phase, multicenter trial evaluating vonoprazan in the treatment of erosive esophagitis (EE). Patient enrollment in PHALCON-EE was completed in November 2020 with topline results expected in the second half of 2021. About VonoprazanVonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown the potential to have rapid, potent, and durable anti-secretory effects as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. The U.S. Food and Drug Administration (FDA) has designated as a qualified infectious disease product (QIDP) and awarded Fast Track status to vonoprazan for the treatment of H. pylori infection in combination with both amoxicillin and clarithromycin and with amoxicillin alone. Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda, which completed 19 Phase 3 trials for vonoprazan and received marketing approval in Japan and numerous other countries in Asia and Latin America. About PhathomPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma. Forward Looking StatementsPhathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the expected availability of topline results from the PHALCON-EE and PHALCON-HP Phase 3 clinical trials; the expected submission of a New Drug Application for the eradication of H. pylori infection, and the potential to receive regulatory and exclusivity benefits as a result of QIDP and Fast Track designations. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom’s business, including, without limitation: potential additional delays in the commencement, enrollment and completion of clinical trials due to the COVID-19 pandemic and other factors outside of Phathom’s control; patients already enrolled in PHALCON-EE and PHALCON-HP may not complete the clinical trials or public health conditions and governmental restrictions may lead Phathom to stop such trials all together, which may adversely impact its trial results and development plans; Phathom’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; QIDP and Fast Track designations may not actually lead to a faster development or regulatory review or extended exclusivity, and would not assure FDA approval of vonoprazan; Phathom’s ability to obtain and maintain intellectual property protection for vonoprazan; Phathom’s ability to comply with its license agreement with Takeda; Phathom’s ability to maintain undisrupted business operations due to the ongoing spread of the COVID-19 coronavirus, including delaying or otherwise disrupting its clinical trials, manufacturing and supply chain, and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. CONTACTS Media Contact:Nick Benedetto1-877-742-8466media@phathompharma.com Investor Contact:Todd Branning 1-877-742-8466ir@phathompharma.com